Is MYX a bargain, page-1286

Shorts should abandon ship.
Although Mayne loses exclusivity of Lexette
min May next year Tolsura increase in sales
will compensate. With reduction of non performing lines and FDA approval of current
pipeline it isn’t difficult to see Gross revenue
of A$850m -A$1B In next 12 to 24 months.
Margins In Specialised Av. 85+%.
Other Generic Av. 50%. It just depends on
management retaining as much as possible
to make Mayne Pharma A Market Darling.
As I say if I were owning any of the 100m Shorts
I would be covering ASAP before there may
be an unexpected announcement by CEO.
with some Price Sensitive Positive News